{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-055687","form_type":"8-K","ticker":"MYO","cik":"0001369290","company_name":"MYOMO, INC.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.115860+00:00","generated_at":"2026-06-02T09:10:03.971109+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Myomo Q1 revenue $3.8M (+9% YoY); backlog record 275 units; net loss $3.8M","bullets":["Revenue $3.8M (+9% YoY); product revenue $3.75M; revenue units 91 (+14%).","Net loss $3.8M ($0.10/share) vs $2.6M loss a year ago; operating loss $3.9M.","Gross margin 61.2% (down 580bps) on lower ASP, higher warranty reserve and material costs.","Record backlog 275 units (+56%), includes 83 Medicare Part B; orders/authorizations 180 (+48%).","Q2 revenue guidance >$5M; FY2024 guidance $28M-$30M; expects operating cash flow breakeven by Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-055687","json":"https://secwatch.observer/filing/0000950170-24-055687.json","markdown":"https://secwatch.observer/filing/0000950170-24-055687.md","text":"https://secwatch.observer/filing/0000950170-24-055687.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369290/000095017024055687/0000950170-24-055687-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369290/000095017024055687/myo-20240508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T09:10:03.971109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a791b3a90ede568f5523f9b05d451c86d659c865","claim":"MYOMO, INC. reported first quarter ended March 31, 2024 results: revenue $3.8 million, net income $3.8 million, or $0.10 per share. Guidance raised.","evidence_excerpt":"Record 275 patients in backlog, includes 180 authorizations and orders in Q1, up 48% over the prior year Record 493 MyoPro candidates added to the pipeline in Q1 Revenue of $3.8 million, up 9% over the prior year Conference call begins at 4:30 p.m. Eastern time today BOSTON (May 8, 2024) – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1369290/000095017024055687/0000950170-24-055687-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$3.8 million"},{"label":"Net income","value":"$3.8 million, or $0.10 per share"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}